ClinicalTrials.gg
Not yet recruitingNCT07569822BLISSUpdated May 6, 2026

Effect of Vibrator Use on Symptoms of Urgency Urinary Incontinence, Sexual Function, and Sleep

An interventional study of Vibrator and Behavioral modification in Urgency Urinary Symptoms, sponsored by Albany Medical College. Not yet recruiting. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-06.

Sponsored by Albany Medical College · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
116
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

This study aims to understand if using a vibrator affects urgency related urinary incontinence. Insights from this study may open new recommendations for treating urinary urgency and incontinence.

Read the detailed description

This is a randomized superiority trial designed to evaluate the efficacy of scheduled vibrator use as an adjunct to standard lifestyle and behavioral modifications for urgency urinary incontinence (UUI) or urgency-predominant mixed urinary incontinence (MUI). UUI is defined as involuntary urine leakage preceded by a sudden, compelling urge to void. This will be identified and confirmed by patient report and screening with urgency-related items on the Urogenital Distress Inventory-6 (UDI-6), with participants required to report urgency-related leakage at least once per week.

Eligible participants will be recruited from the Albany Medical Center Urogynecology clinic during routine outpatient visits. After informed consent and baseline assessment, participants will be randomized 1:1 to either (1) lifestyle and bladder training counseling alone (control arm) or (2) lifestyle and bladder training counseling plus scheduled vibrator use (intervention arm). Participants in the intervention group will be instructed to use a provided FDA-registered Class II wellness vibrator for 5-10 minutes at least three times per week over an eight-week period, while all participants will receive standardized bladder retraining education materials. The primary outcome measure will be change in UDI-6 score, Female Sexual Function Index (FSFI), and Brief Pittsburgh Sleep Quality Index (B-PSQI) from baseline to eight weeks. Secondary outcomes will include validated assessments of quality of life and distress, including the Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12), Patient Global Impression of Improvement (PGI-I), Patient Health Questionnaire-4 (PHQ-4).

The study will be conducted at Albany Medical Center, Department of Obstetrics and Gynecology, Division of Urogynecology and Pelvic Reconstructive Surgery, following approval by the Institutional Review Board (IRB).

02

Conditions studied

  • Urgency Urinary Symptoms

Keywords

  • incontinence
03

In context

Lead sponsor

Albany Medical College is the lead sponsor of 81 studies on the registry; 14 are open to participants now.

Of its 17 completed or terminated interventional studies of FDA-regulated products, 3 (18%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Assigned female at birth.
  • Age ≥18 years.
  • Able to read and speak English.
  • Diagnosis of urgency urinary incontinence or mixed urinary incontinence (based on clinical assessment and UDI-6 urgency questions).
  • Leaks urine at least once per week due to urgency.
  • Postvoid residual volume \<100 mL or a third of the voided volume

Exclusion criteria

Exclusion Criteria:

  • Pelvic organ prolapse beyond the hymen
  • Neurogenic bladder, multiple sclerosis, or other neurologic causes of incontinence.
  • Recurrent urinary tract infection (>3 UTIs in the past year or >2 in the past 6 months).
  • Active urinary tract infection at the time of enrollment.
  • Interstitial cystitis/bladder pain syndrome.
  • Current use of sacral neuromodulation or percutaneous tibial nerve stimulation (PTNS).
  • Bladder Botox injection within the past 6 months.
  • Vibrator use within the past 3 months.
  • Patients uncomfortable with vibrator use
  • Pregnancy or plans for pregnancy during the study period.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
116 participants (estimated)

Study arms

  • Active comparator
    Lifestyle and behavioral modifications

    Lifestyle and behavioral modifications

    Behavioral: Behavioral modification

  • Experimental
    Scheduled vibrator use

    Standard behavioral modifications and vibrator use

    Device: Vibrator · Behavioral: Behavioral modification

Interventions

  • DeviceVibrator

    Scheduled vibrator use

  • BehavioralBehavioral modification

    Guideline based standard lifestyle and behavioral modifications for urgency urinary incontinence

06

What researchers measure

Primary outcomes

  1. Change in score on UDI-6 from baseline to follow-up in 8 weeks.

    Submitted

    Time frame: 12 weeks

Secondary outcomes

  1. Female Sexual Function Index (FSFI)

    The Female Sexual Function Index is a 19-item questionnaire assessing domains of sexual function including desire, arousal, lubrication, orgasm, satisfaction, and pain. Scores range from 2 to 36, with higher scores indicating better sexual function and lower likelihood of dysfunction.

    Time frame: 12 weeks

  2. Brief Pittsburgh Sleep Quality Index (B-PSQI)

    The Brief Pittsburgh Sleep Quality Index is a shortened version of the Pittsburgh Sleep Quality Index that evaluates sleep quality and disturbances over a recent time period. Scores typically range from 0 to 15 (depending on version), with higher scores indicating worse sleep quality.

    Time frame: 12 weeks

  3. Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire, IUGA-Revised (PISQ-IR)

    The PISQ-IR assesses sexual function in women with pelvic floor disorders and includes separate scoring for sexually active and non-sexually active individuals. Scores vary by domain, but are generally transformed to a 0-100 scale, with higher scores indicating better sexual function and condition-specific quality of life.

    Time frame: 12 weeks

  4. Patient Global Impression of Improvement (PGI-I)

    The Patient Global Impression of Improvement is a single-item scale that asks patients to rate their condition after treatment compared to baseline. It ranges from 1 (very much better) to 7 (very much worse), with lower scores indicating better outcomes/improvement.

    Time frame: 12 weeks

  5. Patient Health Questionnaire-4 (PHQ-4)

    The Patient Health Questionnaire-4 is an ultra-brief screening tool combining 2 items for anxiety and 2 for depression. Scores range from 0 to 12, with higher scores indicating greater psychological distress.

    Time frame: 12 weeks

  6. International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF)

    The International Consultation on Incontinence Questionnaire-Short Form evaluates the frequency, severity, and impact of urinary incontinence on quality of life. Scores range from 0 to 21, with higher scores indicating more severe symptoms and worse quality of life impact.

    Time frame: 12 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07569822
Lead sponsor
Albany Medical College
Responsible party
Sponsor
First posted
May 6, 2026
Start date
Jul 1, 2026 (estimated)
Primary completion
Dec 31, 2027 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
May 6, 2026

Study contacts

Vinita Gottipati, MD
Contact
gottipv@amc.edu
518-262-5013

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion